ScottRobertSolomonMD

Hematology • Atlanta, GA

Myeloproliferative Disorder Hematology-Oncology

Physician

Join to view full profile

Dr. Solomon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Solomon's full profile

Already have an account?

Office
5670 Peachtree Dunwoody Rd Ne
Suite 1000
Atlanta, GA 30342
Phone+1 404-255-1930

Fax+1 404-459-8510
Is this information wrong?

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1998 - 2001
University of California (San Francisco)Residency, Internal Medicine, 1995 - 1998
University of Maryland School of MedicineClass of 1995

Certifications & Licensure

CA State Medical License 1997 - Present
GA State Medical License 2005 - 2025
MD State Medical License 2000 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Oct 01
Completed
Phase 2
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer Start of enrollment: 2005 May 01
Terminated
Phase 2
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer Start of enrollment: 2006 Jun 01
Terminated
Phase 2
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) Start of enrollment: 2011 Apr 01
Completed
Phase 2
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant Start of enrollment: 2010 Dec 01
Completed
Phase 2
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases Start of enrollment: 2011 Apr 01
Completed
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients Start of enrollment: 2012 Feb 01
Completed
Phase 2
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant Start of enrollment: 2016 Sep 28
Completed
Phase 2
SEL24/MEN1703 in Patients With Acute Myeloid Leukemia Start of enrollment: 2017 Mar 10
Completed
Phase 1, Phase 2
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL Start of enrollment: 2019 Mar 11
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Ibrutinib and Rituxan for Chronic GVHD Start of enrollment: 2019 Dec 16
Terminated
Phase 2
Roles: Principal Investigator, Contact, Sub-Investigator
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Recruiting
Phase 2
Roles: Principal Investigator
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Start of enrollment: 2016 Jan 06
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease Start of enrollment: 2024 Jan 29
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2020 Feb 05
Terminated
Phase 1
Roles: Contact
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Start of enrollment: 2024 Apr 30
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant Start of enrollment: 2024 Aug 31
Not yet recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Paula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K Nooka, Salomon Manier, Natalie Callander, Luciano J Costa, Ravi Vij, Niza...> ;Future Oncology. 2024 Apr 23
Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant.
Michael T Aubrey, Katelin C Jackson, Xu Zhang, Christina L Roark, H Kent Holland, Scott R Solomon, Lizamarie Bachier-Rodriguez, Melhem M Solh, Lawrence E Morris, Asad ...> ;Transplantation and Cellular Therapy. 2024 Mar 30
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following fail...
Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernande...> ;Future Oncology. 2024 Mar 28
CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.
Scott R Solomon, Bayard L Powell, Jamie Koprivnikar, Catherine Lai, Heather Male, Laura C Michaelis, Laura F Newell, David Sanford, Jack Jenkins, Amy Zelaya, Sheryl Co...> ;Cancers. 2024 Feb 24
2 citations
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis, Alison Sehgal, S...> ;Blood. 2024 Feb 1
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter...
Michael Wang, Tanya Siddiqi, Leo I Gordon, Manali Kamdar, Matthew Lunning, Alexandre V Hirayama, Jeremy S Abramson, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Chara...> ;Journal of Clinical Oncology. 2024 Apr 1
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
Abid, M. B., Hemant S Murthy, Mei-Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly, Ankit Kansagra, Fotios V Michelis, Taiga Nishihori, Mrinal Pat...> ;Blood Advances. 2023 Nov 28
1 citations
Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy.
Catherine J Lee, Tao Wang, Karen Chen, Mukta Arora, Ruta Brazauskas, Stephen R Spellman, Carrie Kitko, Margaret L MacMillan, Joseph A Pidala, Sherif M Badawy, Neel Bha...> ;Transplantation and Cellular Therapy. 2024 Jan 1
3 citations
Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant.
Scott R Solomon, Melhem Solh, Lawrence E Morris, H Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Caitlin Guzowski, Katelin C Jackson, Stacey Brown, Asad Bashey> ;Blood Advances. 2023 Sep 26
17 citations
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Tanya Siddiqi, David G Maloney, Saad S Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N Shah, Rajneesh Nath, Bita Fakhri, Deb...> ;Lancet. 2023 Aug 19
3 citations
Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors.
Asad Bashey, Xu Zhang, Lawrence E Morris, H K Holland, Lizamarie Bachier-Rodriguez, Scott R Solomon, Melhem Solh> ;Blood Advances. 2023 Aug 8
66 citations
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernande...> ;Blood. 2023 Apr 6
5 citations
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
Jeremy S Abramson, Patrick B Johnston, Manali Kamdar, Sami Ibrahimi, Koji Izutsu, Jon Arnason, Bertram Glass, Pim Mutsaers, Matthew Lunning, Julia Braverman, Fei Fei L...> ;Blood Advances. 2022 Dec 13
2 citations
Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.
Catherine J Lee, Tao Wang, Karen Chen, Mukta Arora, Ruta Brazauskas, Stephen R Spellman, Carrie Kitko, Margaret L MacMillan, Joseph A Pidala, Jeffery J Auletta, Sherif...> ;Transplantation and Cellular Therapy. 2022 Oct 1
2 citations
Lineage-Specific Relapse Prediction After Haploidentical Transplantation With Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group...
Scott R Solomon, Michael T Aubrey, Xu Zhang, Katelin C Jackson, Christina L Roark, Brian M Freed, Lawrence E Morris, H Kent Holland, Melhem M Solh, Asad Bashey> ;Transplantation and Cellular Therapy. 2022 Sep 1
53 citations
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transpla...
Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C Hildebrandt, John E Godwin, Patrick M Reagan, Nina Wagner-Johnston, James Essel...> ;The Lancet. Oncology. 2022 Aug 1
163 citations
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with r...
Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Il...> ;Lancet. 2022 Jun 18
56 citations
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation fo...
Leo Luznik, Marcelo C. Pasquini, Brent R. Logan, Robert J. Soiffer, Juan Wu, Steven M. Devine, Nancy L. Geller, Sergio Giralt, Helen E. Heslop, Mary M. Horowitz, Richa...> ;Journal of Clinical Oncology. 2021 Dec 2
43 citations
HLA Informs Risk Predictions after Haploidentical Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
Ephraim J. Fuchs, Shannon R. McCurdy, Scott R. Solomon, Tao Wang, Megan M. Herr, Dipenkumar Modi, Michael R. Grunwald, Taiga Nishihori, Michelle Kuxhausen, Stephanie F...> ;Blood. 2021 Nov 1
4 citations
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)
Hagop M. Kantarjian, Kebede H. Begna, Jessica K. Altman, Stuart L. Goldberg, Mikkael A. Sekeres, Stephen A. Strickland, Martha Arellano, David F. Claxton, Maria R. Bae...> ;Cancer. 2021 Aug 23
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
Mahasweta Gooptu, Rizwan Romee, Andrew St Martin, Mukta Arora, Monzr Al Malki, Joseph H Antin, Christopher N Bredeson, Claudio G Brunstein, Saurabh Chhabra, Ephraim J ...> ;Blood. 2021 Jul 22
73 citations
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a ra...
Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Dale L. B...> ;The Lancet. Haematology. 2021 Jul 1
3 citations
A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant ...
Melhem Solh, Gabriel Hinojosa, Justin LaPorte, Scott R. Solomon, Lawrence E. Morris, Xu Zhang, H. Kent Holland, Asad Bashey> ;Advances in Hematology. 2021 Mar 23
11 citations
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: Phase 3 post hoc analyses
Tara L. Lin, David A. Rizzieri, Daniel H. Ryan, Gary J. Schiller, Jonathan E. Kolitz, Geoffrey L. Uy, Donna E. Hogge, Scott R. Solomon, Matthew J. Wieduwilt, Robert J....> ;Blood Advances. 2021 Mar 23
8 citations
Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor...
Melhem Solh, Jimena Baron, Xu Zhang, Asad Bashey, Lawrence E. Morris, H. Kent Holland, Scott R. Solomon> ;Biology of Blood and Marrow Transplantation. 2020 Nov 1
Join now to see all

Abstracts/Posters

SEL120 _ a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinica...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Mor...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Inciden...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hemato...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Trans...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019